<DOC>
	<DOCNO>NCT00278954</DOCNO>
	<brief_summary>The main objective study see GAMMAPLEX efficacious respect Food Drug Administration ( FDA ) minimal requirement ( 1 serious , acute , bacterial infection per subject per year ) subject Primary Immunodeficiency Diseases ( PID ) . The secondary objective assess safety tolerability GAMMAPLEX determine GAMMAPLEX pharmacokinetic ( PK ) profile comparable intact Immunoglobulin G ( IgG ) subject PID .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics Gammaplex Primary Immunodeficiency Diseases .</brief_title>
	<detailed_description>Primary Efficacy Variable The primary variable number serious , acute , bacterial infections/subject/year , base total follow event defined FDA : bacterial Pneumonia , bacteremia/sepsis , osteomyelitis/septic arthritis , visceral abscess , bacterial meningitis . Secondary Efficacy Variables Secondary efficacy determine use follow variable : number day work/school missed infection per subject year ; number day hospitalization infection per subject year ; number visit physician acute problem and/or number visit hospital emergency room per subject year ; infection document fever positive result radiograph and/or culture ; number infectious episode per subject per year ; number day therapeutic antibiotics.These data enter subject diary , confirmed physician , enter electronic-CRF ( e-CRF ) . Safety Variables . The variable use assess safety follow : adverse event ( AEs ) ; vital sign ; clinical laboratory test Direct Coombs ' Test ; transmission virus ; physical examination . Test product , dose/mode administration , batch number ( ) : The GAMMAPLEX dose 300-800 mg/kg/infusion ( milligram per killgram per infusion ) every 21 28 day , intravenously . At least 2 batch use study 1 batch give infusion . Duration treatment : The total duration treatment 12 month .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . The subject 3 year age old , either sex , belong ethnic group , minimum weight 27.5 kg . This weight base amount blood require testing . If subject participate PK segment , minimum weight require 37 kg . 2 . The subject primary immunodeficiency disease , significant component hypogammaglobulinemia and/or antibody deficiency ( e.g . ( exempli gratia / example ) , common variable immunodeficiency , Xlinked autosomal form agammaglobulinemia , hyperimmunoglobulin M ( hyperIgM ) syndrome , WiskottAldrich Syndrome ) . Isolated deficiency single IgG subclass , specific antibody without hypogammaglobulinemia per se , qualify inclusion . 3 . The subject receive license investigational ( Phase III IIIb ) immunoglobulin intravenous ( IGIV ) replacement therapy dose change + 50 % mean dose least 3 month study entry 300 800 mg/kg/infusion . The infusion interval must 21 28 day inclusive . The subject must maintain trough level least 300 mg/dL ( milligram per decilitre ) baseline serum IgG level ( define initiation gamma globulin treatment subject ) . The trough level must 600 mg/dL . 4 . Trough level IgG dose IGIV , treatment interval , trade name IGIV treatment use last 2 consecutive routine ( licensed investigational product ) must document subject first infusion study administer . 5 . If subject female childbearing potential , must negative result Human Chorionic Gonadotrophin ( HCG ) base pregnancy test . 6 . If subject female become sexually active , must practice contraception use method proven reliability duration study . 7 . The subject willing comply aspect protocol , include blood sampling , duration study . 8 . The subject sign informed consent form ( least 18 year old ) subject 's parent legal guardian sign informed consent form . If appropriate , subject sign child assent form ( See Section 12.3 ) . Subjects exclude follow exclusion criterion meet : 1 . The subject history severe anaphylactic reaction blood bloodderived product . 2 . The subject know intolerant component GAMMAPLEX , sorbitol ( i.e . ( id est / ) , intolerance fructose ) . 3 . The subject selective immunoglobulin A ( IgA ) deficiency , history reaction product contain IgA , history antibody IgA . 4 . Subjects complete study subject withdraw participate study second time . 5 . The subject currently receive , receive , investigational agent , immune serum globulin ( ISG ) preparation evaluate Phase III IIIb study , within prior 3 month . 6 . The subject expose blood blood product derivative within last 6 month , commercially available IGIV form commercially available license ISG ISG product Phase III IIIb study . 7 . The subject pregnant nursing . 8 . The subject positive follow screening : Serological test Human immunodeficiency virus ( HIV ) 1 &amp; 2 , Hepatitis C virus ( HCV ) , Hepatitis B surface antigen ( HBsAg ) Nucleic Acid test ( NAT ) HCV NAT HIV 9 . The subject , screening , level great 2.5 time upper limit normal defined central laboratory following : Alanine transaminase ( ALT ) Aspartate transaminase ( AST ) 10 . The subject severe renal impairment ( define serum creatinine great 2 time upper limit normal Blood urea nitrogen ( BUN ) great 2.5 time upper limit normal range laboratory analysis ) ; subject dialysis ; subject history acute renal failure . 11 . The subject know abuse alcohol , opiates , psychotropic agent , chemical drug , do within past 12 month . 12 . The subject history deep vein thrombosis ( DVT ) , thrombotic complication IGIV therapy . 13 . The subject suffers acute chronic medical condition ( e.g. , renal disease predispose condition renal disease , coronary artery disease , protein lose state ) , opinion investigator , may interfere conduct study . 14 . The subject acquire medical condition , chronic lymphocytic leukemia , lymphoma , multiple myeloma , chronic recurrent neutropenia ( Absolute neutrophil count ( ANC ) &lt; 1000 x 109/L ) . 15 . The subject receiving follow medication : Immunosuppressive drug The subject receive follow medication : Steroids ( longterm daily , &gt; 0.15 mg /kg/day prednisone prednisolone equivalent dose corticosteroid ) The requirement burst intermittent course would exclude subject . Immunomodulatory drug 16 . The subject noncontrolled arterial hypertension ( systolic blood pressure &gt; 160 mmHg ( millimeter mercury ) and/or diastolic blood pressure &gt; 100 mmHg ) . 17 . The subject anemia ( hemoglobin &lt; 10 g/dL ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Primary Antibody Deficiency</keyword>
	<keyword>Common variable hypogammaglobulinemia</keyword>
	<keyword>X-linked hypogammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Immunodeficiency hyper-IgM</keyword>
	<keyword>Wiskott-Aldrich Syndrome</keyword>
</DOC>